ArticleDermatology and therapy2026
Efficacy and Safety of a Topical Skincare Regimen with Tripeptide/Hexapeptide following Aesthetic Procedures: Analysis of Two Randomized, Split-Face Trials in Asian Subjects.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionPre- and postprocedure skin care is crucial for patients undergoing energy-based device (EBD) treatments. A serum containing a proprietary blend of peptides to support extracellular matrix remodeling (TriHex Technology
methodsTwo prospective, randomized, evaluator-blind, split-face studies were conducted. In the FCL study (n = 26), subjects applied a reference moisturizer on the entire face and the serum on an assigned hemi-face for 2 weeks preprocedure. Postprocedure, the serum and moisturizer were applied to opposite hemi-faces for 3 days, followed by the preprocedure regimen until day 14. In the RFMN study (n = 25), serum and moisturizer were applied to opposite hemi-faces immediately postprocedure for 3 days, followed by serum on the assigned hemi-face and moisturizer on the entire face until day 14. Blinded clinical evaluations, self-assessments, and skin measurements were performed on days 0, 1, 3, 7, and 14.
resultsAll 26 subjects (18 female, 8 male) completed the FCL study and 25 (24 female, 1 male) completed the RFMN study. Overall, the serum-treated side showed superior or comparable recovery versus control across multiple parameters. The primary endpoint of investigator-assessed erythema showed significant within-side improvement on both sides in both studies, while between-side differences did not reach statistical significance. Among secondary endpoints, the serum-treated side showed significantly greater recovery that withstood multiplicity correction for transepidermal water loss (TEWL) at day 3, and edema, VISIA redness, and tactile roughness at day 14 in the FCL study, while crusting at day 3 showed numerical improvement. In the RFMN study, the serum-treated side showed significantly greater edema reduction at day 7 that withstood correction; numerical improvements were observed for pain and heat sensation at day 1 and for erythema and crusting at day 7. On day 14, significantly more subjects reported better recovery on the serum-treated side (FCL, 81.8%; RFMN, 100%; p < 0.05). Safety was favorable with few mild adverse events.
conclusionsIn these two exploratory studies, the topical serum containing TriHex Technology
trial registrationChictr.org.cn identifiers: ChiCTR2400089516 and ChiCTR2400089424.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.